Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
CONCLUSIONS: Significant disparities in cancer care exist among geographic locations. Geographic differences in survival appear more prominent when highly effective therapies are available.PMID:37690903 | DOI:10.1016/j.clml.2023.08.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 10, 2023 Category: Cancer & Oncology Authors: Koji Sasaki Kiyomi Morita Hagop Kantarjian Guillermo Garcia-Manero Elias Jabbour Farhad Ravandi Marina Konopleva Gautam Borthakur William Wierda Naval Daver Koichi Takahashi Courtney DiNardo Guillermo Montalban Bravo Ghayas C Issa Sherry A Pierce Kelly A Source Type: research
The Impact of CD34 < sup > + < /sup > Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma
CONCLUSION: Although bortezomib is not considered stem-cell toxic, it may be associated with lower stem cell collection yields. Bortezomib's efficacy at induction may partially explain the improved outcomes, however, other factors may be involved, and are discussed. We can conclude that with our large cohort and long follow-up, high stem-cell mobilization does not appear to predict for a long-term survival advantage.PMID:37689547 | DOI:10.1016/j.clml.2023.07.014 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 9, 2023 Category: Cancer & Oncology Authors: Eyal Lebel Katherine Lajkosz Esther Masih-Khan Donna Reece Suzanne Trudel Rodger Tiedemann Anca Prica Vishal Kukreti Christine Chen Source Type: research
The Impact of CD34 < sup > + < /sup > Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma
CONCLUSION: Although bortezomib is not considered stem-cell toxic, it may be associated with lower stem cell collection yields. Bortezomib's efficacy at induction may partially explain the improved outcomes, however, other factors may be involved, and are discussed. We can conclude that with our large cohort and long follow-up, high stem-cell mobilization does not appear to predict for a long-term survival advantage.PMID:37689547 | DOI:10.1016/j.clml.2023.07.014 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 9, 2023 Category: Cancer & Oncology Authors: Eyal Lebel Katherine Lajkosz Esther Masih-Khan Donna Reece Suzanne Trudel Rodger Tiedemann Anca Prica Vishal Kukreti Christine Chen Source Type: research
A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure
CONCLUSION: Pomalidomide-based combination regimens were effective in patients with RRMM previously treated with lenalidomide and tended to be associated with better outcomes when used earlier in the treatment pathway. A drug class switch may not always be necessary when making treatment decisions for patients with RRMM for whom the benefits of lenalidomide have been exhausted, although this must be supported by comparative studies.PMID:37684184 | DOI:10.1016/j.clml.2023.07.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 8, 2023 Category: Cancer & Oncology Authors: Faith E Davies Xavier Leleu Prisca Vogel Sujith Dhanasiri Pauline Le Nouveau Katja Weisel Source Type: research
Loss of CD34 < sup > + < /sup > Cells and Effect of the Number of Viable Cryopreserved CD34 < sup > + < /sup > Cells in the Infused Blood Grafts on Hematologic Recovery, Progression-Free Survival and Overall Survival in NHL Patients After Autologous Stem Cell Transplantation
CONCLUSIONS: G-CSF type used in mobilization and mobilization capacity were found to correlate with viable CD34+ cell loss during processing and storage. Most importantly, low infused viable CD34+ cell count did not seem to impact on PFS or OS.PMID:37684185 | DOI:10.1016/j.clml.2023.08.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 8, 2023 Category: Cancer & Oncology Authors: Anu Partanen Antti Turunen Jaakko Valtola Marja Py örälä Outi Kuittinen Hanne Kuitunen Kaija Vasala Karri Penttil ä Taru Kuittinen Pentti M äntymaa Jukka Pelkonen Esa Jantunen Ville Varmavuo Source Type: research
